Loading
A phase 3 trial of capecitabine, carboplatin, cisplatin and sacituzumab govitecan in triple-negative breast cancer, run by GBG Forschungs GmbH, active but no longer recruiting.
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer. ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is planned at 1332 participants. Primary completion is estimated at 2027-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Capecitabine, Carboplatin, Cisplatin, Sacituzumab govitecan. Registered primary measures: Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice..
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Capecitabine, Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Cisplatin and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/